Injuries & Orthopedics
Peptides for Burn Recovery: The Honest Evidence Review
LL-37, GHK-Cu, thymosin β4/TB-500 and BPC-157 all have real wound-healing biology — but not a single controlled human burn trial. A clinical-editorial ranking of what the evidence actually supports in 2026.
Burn healingWound peptidesLL-37BPC-157Evidence-graded
The quick verdict
No peptide has ever been tested in a controlled human burn trial — here is what the biology, animal models, and non-burn human data actually show, ranked by evidence strength.
- Best overall
- LL-37 (human cathelicidin) — The only peptide here with Phase IIb-level human wound data and the most burn-logical mechanism (antimicrobial + healing) — though its evidence is in chronic ulcers, is endpoint-mixed, and includes zero burn trials.
- Best value
- GHK-Cu (copper tripeptide) — A legal, inexpensive topical cosmetic with strong skin-regeneration biology and human safety data — but its only controlled human wound trial was objectively negative and it cannot help full-thickness burns.
- Best for Direct burn-model preclinical signal
- BPC-157 — The most burn-specific animal data of the group (mouse flame-burn cream and rat alkali-burn hydrogel), but with zero human evidence, a WADA ban, and gray-zone legal status.
How we evaluated
We ranked each peptide by evidence strength multiplied by burn relevance, strictly separating completed human trials from animal models and anecdote. A peptide with strong non-burn human data can rank above one with only animal burn data, because human-outcome evidence — even in a related wound — outweighs preclinical burn signal. No peptide receives a grade above C for burns specifically, because none has a controlled human burn trial.
- Human burn evidence. Completed controlled trials in actual human burns. None of these peptides has any — the decisive gap.
- Human wound evidence (non-burn). RCTs in chronic ulcers or laser-wound settings, weighted for how transferable that biology is to burns.
- Burn-model preclinical data. Animal flame/alkali/corneal burn studies showing re-epithelialization, angiogenesis, or infection control.
- Burn-mechanism relevance. Whether the peptide targets the biology burns actually fail on: barrier loss, perfusion, and infection.
- Safety & legal status. FDA approval, compounding status, product-purity risk, and WADA prohibition.
Rating scale: 1–5 stars reflecting evidence strength × burn relevance; grades A–D map to human-RCT (A/B), preclinical-only (C), and anecdotal/marketing (D). No peptide earns above C for burns.
Last verified .
At a glance
| # | Name | Evidence | Rating | Best for | Pricing |
|---|---|---|---|---|---|
| 1 | LL-37 (human cathelicidin) | C | 3.0 | Understanding why infection control makes LL-37 the most burn-logical peptide — not for use on a burn | Unapproved / compounded only |
| 2 | GHK-Cu (copper tripeptide) | C | 2.5 | Appreciating skin-regeneration biology and its hard mechanistic limit in deep burns | Topical cosmetic; varies |
| 3 | Thymosin β4 (Tβ4) & TB-500 | C | 2.5 | Seeing how strong animal wound data can still fail in controlled human trials | Research chemical / unapproved |
| 4 | BPC-157 | C | 2.0 | Recognizing the widest promise-versus-proof gap in the burn-peptide category | Research chemical / unapproved |
| 5 | Evidence-based burn care (the honest benchmark) | A | 5.0 | Anyone with a significant burn — the evidence-based standard of care | Clinical care; varies |
LL-37 (human cathelicidin)
Strongest human wound data, most burn-logical mechanism — but not in burns
LL-37 is the only human cathelicidin antimicrobial peptide, a 37-residue peptide cleaved from hCAP18 that combines bactericidal and anti-biofilm activity with immunomodulatory, pro-angiogenic, and pro-migratory effects. It is the most logically burn-relevant peptide here because burns fail chiefly through infection, and LL-37 is simultaneously antimicrobial and healing-promoting. Its human evidence is the strongest of the group — but in chronic ulcers, not burns. The multicenter double-blind HEAL trial in 148 treated patients with hard-to-heal venous leg ulcers was negative on its primary endpoint (complete closure roughly 26.5% / 24.7% / 25.3% for low dose / high dose / placebo), with a positive post-hoc subgroup in wounds larger than 10 cm2. An earlier smaller venous-ulcer RCT reported a favorable healing response, and a small diabetic-foot-ulcer RCT improved granulation index but not wound area. For burns specifically, the case is purely mechanistic and preclinical: LL-37 clears burn-type pathogens including MRSA in animal wound-infection models, but no human burn trial exists. It is not FDA-approved and is available only through compounding.
Strengths
- Only peptide here with Phase IIb-level human wound-healing data (chronic ulcers)
- Dual mechanism uniquely suited to burns: broad antimicrobial (MRSA, P. aeruginosa) plus pro-healing
- Well tolerated topically in trials, with mostly mild/moderate local reactions and no drug-related serious adverse events
Weaknesses
- Zero human burn trials; the burn case is entirely mechanistic and preclinical
- Largest human RCT (HEAL) was negative on its primary endpoint; benefit rests on a post-hoc subgroup
- High-concentration LL-37 can be cytotoxic/pro-inflammatory and is implicated in rosacea; not FDA-approved
- Best for
- Understanding why infection control makes LL-37 the most burn-logical peptide — not for use on a burn
- Pricing
- Unapproved / compounded only
Source: Mahlapuu et al., Wound Repair Regen 2021 (HEAL LL-37 Phase IIb RCT)
GHK-Cu (copper tripeptide)
Best-characterized skin peptide — but negative human wound trial and useless in deep burns
GHK-Cu is a naturally occurring copper-binding tripeptide (glycyl-L-histidyl-L-lysine:Cu2+) isolated from human plasma in the 1970s and the most-studied skin-regeneration peptide, used widely as a topical cosmetic ingredient. It binds copper with very high affinity, delivers non-toxic copper into cells, modulates collagen, elastin, proteoglycan, and glycosaminoglycan synthesis at nanomolar levels, regulates a very large gene set in fibroblasts, recruits endothelial cells, raises VEGF, and acts as an antioxidant. Despite that biology, its human evidence is limited and not burn-specific. The one controlled human study in a wound-like setting — GHK-Cu skincare on CO2-laser-resurfaced facial skin (n=13, randomized, blinded) — found no significant objective benefit for erythema resolution or skin quality, only higher subjective satisfaction. Its remaining human data are cosmetic photoaging trials. A proof-of-concept acute-wound trial (CuHeal) is registered and ongoing. Crucially, GHK-Cu acts on viable fibroblasts and dermal structures, so while plausibly relevant to superficial or partial-thickness burns, it is mechanistically ineffective in full-thickness burns that destroy the very cells it needs.
Strengths
- Best-characterized skin-regeneration peptide with substantial mechanistic and human topical-safety data
- Legal as a topical cosmetic ingredient and inexpensive relative to research-chemical peptides
- Plausible biology for superficial/partial-thickness skin repair (collagen, angiogenesis, antioxidant effects)
Weaknesses
- Only controlled human wound-context trial (laser-resurfaced skin) was objectively negative
- Mechanistically useless in full-thickness burns — no viable fibroblasts for it to act on
- No validated burn protocol; injectable copper-peptide products risk copper overload and are not FDA-approved
- Best for
- Appreciating skin-regeneration biology and its hard mechanistic limit in deep burns
- Pricing
- Topical cosmetic; varies
Source: Miller et al., Arch Facial Plast Surg 2006 (GHK-Cu laser-resurfacing RCT)
Thymosin β4 (Tβ4) & TB-500
Deepest animal dermal/corneal-burn data — but the human program failed
Thymosin β4 (Tβ4) is a 43-amino-acid actin-sequestering regenerative peptide; TB-500 is a synthetic acetylated fragment marketed for recovery. They are not the same molecule, and data for one do not transfer to the other. The preclinical burn-adjacent data are strong: in a rat full-thickness wound, topical or systemic Tβ4 increased re-epithelialization by roughly 42% at day 4 and 61% at day 7, with more collagen, more angiogenesis, and stimulated keratinocyte migration; Tβ4 also improves corneal-burn healing in rabbits via MMP-2/TIMP-2 regulation and accelerates repair in diabetic, aged, and burn animal models. But the human story is discouraging. Full-length Tβ4 is the only peptide here to reach controlled human dermal-wound trials, and they were safe but efficacy-negative: RegeneRx's topical RGN-137 gel met safety endpoints yet failed complete-wound-closure efficacy in a Phase 2 pressure-ulcer trial and never reached approval. TB-500, the injectable fragment sold as a research chemical, has no human data at all. Both are prohibited by WADA at all times as growth factors and non-approved substances.
Strengths
- Deepest dermal and corneal-burn animal data of the group (~42–61% faster re-epithelialization in a rat model)
- Coherent regenerative mechanism: actin-sequestration enabling keratinocyte and endothelial migration
- Full-length Tβ4 reached controlled human dermal-wound trials and met safety endpoints
Weaknesses
- The one human dermal-wound program (RGN-137) FAILED its efficacy endpoint and never reached approval
- TB-500 (the marketed fragment) has zero human data — its case is entirely by-analogy
- Prohibited by WADA at all times (S0 + S2.3); sold as a research chemical not for human use
- Best for
- Seeing how strong animal wound data can still fail in controlled human trials
- Pricing
- Research chemical / unapproved
Source: Malinda et al., FASEB J 1999 (Tβ4 accelerates wound healing, rat)
BPC-157
Most direct burn-model data — and zero human evidence
BPC-157 is a synthetic pentadecapeptide derived from a gastric protein, marketed for tissue repair; it is not FDA-approved and is sold as a research chemical. It has the most burn-direct preclinical data of this group. A mouse flame-burn study reported that a BPC-157 cream reversed poor re-epithelialization, increased burned-skin breaking strength and elongation, reduced inflammatory cells and water content, and attenuated secondary gastric lesions — outperforming silver sulfadiazine on several measures. In a rat alkali-burn model, topical BPC-157 hydrogel (800 ng/mL) raised day-18 wound closure to about 81.5% versus roughly 60% in controls, with better granulation, re-epithelialization, and dermal remodeling, upregulated VEGF, and HUVEC proliferation, migration, and tube formation via ERK1/2 signaling. A broad review catalogs BPC-157 across burn and other wound models. But the entire base is animal and in-vitro: there is no human evidence for burns or any wound indication. Legally it sits in a gray zone — removed from FDA 503A Category 2 in April 2026 but not authorized for compounding — and it is prohibited by WADA at all times.
Strengths
- Most direct burn-model preclinical data (mouse flame-burn cream and rat alkali-burn hydrogel)
- Outperformed silver sulfadiazine on several measures in the mouse burn study
- Coherent pro-angiogenic mechanism (VEGF upregulation, HUVEC tube formation via ERK1/2)
Weaknesses
- Zero human evidence for burns or any wound indication — entirely animal/in-vitro
- Unapproved research chemical with no human burn safety data; infection and purity hazards
- Regulatory gray zone (removed from 503A Cat 2 Apr 2026 but not authorized) and prohibited by WADA at all times
- Best for
- Recognizing the widest promise-versus-proof gap in the burn-peptide category
- Pricing
- Research chemical / unapproved
Source: Huang et al., Drug Des Devel Ther 2015 (BPC-157 alkali-burn wound healing, rat)
Evidence-based burn care (the honest benchmark)
The interventions with real human burn evidence are not peptides
This entry is not a peptide — it is the honest benchmark every peptide above is measured against. The interventions with actual human evidence for better burn outcomes are prompt burn-center referral, debridement, modern antimicrobial dressings, fluid resuscitation, early excision and grafting, and structured scar management. Per the American Burn Association, specialist care is mandatory for any full-thickness burn at any age, partial-thickness burns over roughly 10% total body surface area, burns of the face, hands, feet, genitalia, perineum, or major joints, and all electrical, chemical, or inhalation injuries. These pathways are backed by consensus guidelines and decades of clinical outcome data — not extrapolation from rodent models. Re-epithelialization, infection control, and scar quality in real burns are driven by this standard of care, none of which a peptide substitutes for. Applying any unapproved peptide to a burn risks infection, delayed grafting, and interference with evidence-based treatment. Included here as rank 5 to make the comparison honest: it is the only option in this list graded A, because it is the only one with controlled human burn evidence.
Strengths
- Backed by specialty-society consensus guidelines and decades of human burn-outcome data
- Directly manages the three problems burns fail on: barrier loss, perfusion, and infection
- The only option in this comparison with genuine controlled human burn evidence (Grade A)
Weaknesses
- Requires access to a burn center or qualified clinician — not a self-applied product
- Not a peptide, so it offers no shortcut for those seeking an at-home 'healing' agent
- Best for
- Anyone with a significant burn — the evidence-based standard of care
- Pricing
- Clinical care; varies
Source: American Burn Association — Burn Center Referral Criteria
Frequently asked
Is there any peptide proven to heal burns in humans?
No. As of 2026, no peptide has a completed controlled human burn trial — none has been shown to speed re-epithelialization, reduce scarring, or improve any burn outcome in people. The strongest human wound-healing data belong to LL-37, but those come from chronic venous leg ulcers and diabetic foot ulcers, a different wound biology, and are endpoint-mixed: the largest RCT was negative on its primary endpoint. Every burn-specific data point is animal. Mechanism is real, but mechanism is not proof of a human burn benefit.
Could GHK-Cu help a minor sunburn or superficial burn?
There is no burn trial to support it. GHK-Cu is a well-characterized topical cosmetic copper-tripeptide with genuine skin-regeneration biology, but its only controlled human wound-context study, on CO2-laser-resurfaced skin, found no significant objective benefit. Critically, it works by acting on viable dermal fibroblasts, so it is mechanistically useless in full-thickness burns that destroy those cells. Applying any product to an open burn risks infection and should only happen under clinician supervision. Standard burn first aid and professional evaluation remain the evidence-based answer.
Why is LL-37 the most burn-relevant peptide despite weak burn data?
Because burn wounds fail chiefly through infection — sepsis is a leading cause of burn death — and LL-37, the only human cathelicidin, is uniquely both broadly antimicrobial and pro-healing. It shows activity against classic burn colonizers including MRSA and Pseudomonas aeruginosa while also driving keratinocyte migration and angiogenesis. A single agent that both kills burn pathogens and accelerates closure is the most logical fit for burn biology. But logical is not proven: LL-37's human evidence is in chronic ulcers and is mixed, its antimicrobial-in-burns rationale is preclinical, and there is still no human burn trial.
Are TB-500 and BPC-157 safe to use on a burn?
No supported basis exists. Both are sold as research chemicals not for human use, neither is FDA-approved, and both carry infection and product-purity risks plus a WADA all-times ban. TB-500 is a synthetic fragment with no human data of any kind, and the studied full-length molecule, thymosin β4 (RGN-137), actually failed its human chronic-wound efficacy endpoint. BPC-157 has the most direct burn-model preclinical data but zero human evidence. Applying any of these to a burn is unsupported and can introduce infection or delay definitive burn care.
When must a burn be seen by a specialist rather than self-treated?
Per American Burn Association referral criteria, seek burn-center evaluation for any full-thickness (third-degree) burn at any age; partial-thickness burns over roughly 10% of total body surface area; any burn of the face, hands, feet, genitalia, perineum, or major joints; and all electrical, chemical, or inhalation injuries. These carry high risks of infection, scarring, contracture, and systemic complications that outpatient care cannot manage. Applying unapproved substances, including peptides, to such burns risks infection and can delay grafting. When in doubt, treat a significant burn as a medical emergency.
Do the '30% faster burn healing' claims online hold up?
No. Claims of a specific percentage of faster burn healing or precise scar-reduction figures are extrapolated from animal models or non-burn human wounds, not from human burn outcomes. For example, the roughly 42 to 61 percent faster re-epithelialization figure cited for thymosin β4 comes from a rat full-thickness wound model, and BPC-157's improved closure numbers come from a rat alkali-burn study. Neither is a human burn result. Marketing that presents these as human burn benefits is misrepresenting preclinical data, which is exactly why this category is graded C for burns despite genuinely interesting biology.